Upsher-Smith intros generic Cardura
Upsher-Smith Labs has launched its generic Cardura (doxazosin) tablets. The Maple Grove, Minn.-based company received approval from the Food and Drug Administration for its copy of the Pfizer drug on April 17.
The drug is indicated to treat signs and symptoms of benign prostatic hyperplasia and to treat hypertension.
Upsher-Smith’s generic Cardura will be available in 100-count bottles of 1-, 2-, 4- and 8-mg dosage strength tablets. The product had a U.S. market size of roughly $51.2 million for the 12 months ended January 2018, according to IQVIA data.
The drug is indicated to treat signs and symptoms of benign prostatic hyperplasia and to treat hypertension.
Upsher-Smith’s generic Cardura will be available in 100-count bottles of 1-, 2-, 4- and 8-mg dosage strength tablets. The product had a U.S. market size of roughly $51.2 million for the 12 months ended January 2018, according to IQVIA data.